BioSpace News Archive

The global sickle cell disease treatment market size is estimated to garner around USD 50.45 billion by 2032 and is expanding at a healthy CAGR of 35.1% from 2023 to 2032.

Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per share.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has appointed Amy Ables, Ph.D . as chief strategy officer of the organization, effective immediately.

Viriom Inc., dedicated to advancing a pipeline of highly effective and broadly affordable treatments targeting infectious and malignant diseases globally, announces the successful completion and positive results of Phase I clinical trial for AV5124, a novel inhibitor of influenza virus replication.

Akebia Therapeutics, Inc. announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28th at 10:30 a.m. EST.

Alzamend Neuro, Inc. announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration for the initiation of study AL001-MDD01, a Phase IIA clinical study of AL001 for treatment of patients with MDD.

Fuse Oncology, a trailblazing leader in radiation oncology software solutions, is pleased to announce the appointment of Dr. Christel Smith as its new Chief Technology Officer.

NeuroMetrix, Inc. announced that it will effect a one-for-eight reverse split of its common stock, effective at 5:00 pm on November 21, 2023.

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced its Active Intelligence® platform surpassed more than 100,000 total joint replacement surgeries across the globe.

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced that Derrick Sung has been appointed chief financial officer of the company.